Imunon Inc (IMNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imunon Inc (IMNN) has a cash flow conversion efficiency ratio of -1.088x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.44 Million) by net assets ($4.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Imunon Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Imunon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IMNN current and long-term liabilities for a breakdown of total debt and financial obligations.
Imunon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imunon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Great Western Exploration Ltd
AU:GTE
|
-0.013x |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
0.490x |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
-0.010x |
|
Manhattan Corporation Ltd
AU:MHC
|
-0.037x |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
-0.039x |
|
Viking Mines Ltd
AU:VKA
|
-0.290x |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
N/A |
|
Bhakti Agung Propertindo
JK:BAPI
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Imunon Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Imunon Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see Imunon Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.24 Million | $-18.85 Million | -4.442x | -212.65% |
| 2023-12-31 | $13.39 Million | $-19.02 Million | -1.421x | -80.42% |
| 2022-12-31 | $29.33 Million | $-23.10 Million | -0.788x | -170.85% |
| 2021-12-31 | $55.80 Million | $-16.22 Million | -0.291x | +65.35% |
| 2020-12-31 | $18.61 Million | $-15.62 Million | -0.839x | +39.69% |
| 2019-12-31 | $14.56 Million | $-20.26 Million | -1.392x | -312.24% |
| 2018-12-31 | $20.86 Million | $-7.04 Million | -0.338x | +45.84% |
| 2017-12-31 | $26.70 Million | $-16.64 Million | -0.623x | +77.19% |
| 2016-12-31 | $6.73 Million | $-18.38 Million | -2.733x | -167.43% |
| 2015-12-31 | $20.39 Million | $-20.83 Million | -1.022x | -57.08% |
| 2014-12-31 | $32.83 Million | $-21.35 Million | -0.651x | -115.28% |
| 2013-12-31 | $31.52 Million | $-9.53 Million | -0.302x | +83.68% |
| 2012-12-31 | $11.96 Million | $-22.14 Million | -1.851x | -113.22% |
| 2011-12-31 | $26.19 Million | $-22.74 Million | -0.868x | -129.72% |
| 2010-12-31 | $-4.58 Million | $-13.37 Million | 2.921x | +3251.52% |
| 2009-12-31 | $10.04 Million | $-930.33K | -0.093x | -180.16% |
| 2008-12-31 | $19.73 Million | $2.28 Million | 0.116x | +136.99% |
| 2007-12-31 | $30.65 Million | $-9.58 Million | -0.313x | -113.84% |
| 2006-12-31 | $-3.20 Million | $-7.23 Million | 2.260x | +195.98% |
| 2005-12-31 | $3.43 Million | $-8.06 Million | -2.354x | -102.16% |
| 2004-12-31 | $11.97 Million | $-13.94 Million | -1.165x | -72.38% |
| 2003-12-31 | $13.45 Million | $-9.09 Million | -0.676x | +88.76% |
| 2002-12-31 | $1.52 Million | $-9.11 Million | -6.008x | -157.70% |
| 2001-12-31 | $2.67 Million | $-6.22 Million | -2.332x | -426.22% |
| 2000-12-31 | $8.73 Million | $-3.87 Million | -0.443x | +80.74% |
| 1999-12-31 | $1.00 Million | $-2.30 Million | -2.300x | -301.53% |
| 1998-12-31 | $-1.85 Million | $-2.11 Million | 1.141x | +143.19% |
| 1997-12-31 | $-2.46 Million | $-1.15 Million | 0.469x | +316.77% |
| 1996-12-31 | $6.76 Million | $-1.46 Million | -0.216x | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-2… Read more